Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/181837METHOD FOR RESCUING INFLUENZA VIRUS AND COMPOSITION THEREFOR
WO 17.09.2020
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2019/121905 Applicant ZHEJIANG SENWEI BIOPHARMACEUTICAL DEVELOPMENT CO., LTD. Inventor DAI, Dongsheng
Provided are a new method for rescuing an influenza virus and a composition therefor. The method comprises providing a host cell stably integrated with and expressing influenza virus PA, PB1, PB2 and NP genes, and introducing an influenza virus rescue system in which a stop codon is introduced into the PA, PB1, PB2 and NP genes respectively into the host cell to achieve virus rescue. The produced virus particles can be used as a live attenuated influenza vaccine, which is characterized in that, since the genes encoding the related proteins are mutated, it has no replication and proliferation ability in human and normal animal cells, and replication and proliferation can be achieved only in the host cells constructed above and it can fully stimulate the body immunity and effectively protect the body while ensuring the safety.
2.WO/2020/183955MEMBRANE FOR CONCENTRATING BIOLOGICAL PARTICLES, CONCENTRATING DEVICE, CONCENTRATING SYSTEM, CONCENTRATING METHOD, AND METHOD FOR DETECTING BIOLOGICAL PARTICLES
WO 17.09.2020
Int.Class C12M 1/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
12with sterilisation, filtration, or dialysis means
Appl.No PCT/JP2020/002968 Applicant TEIJIN LIMITED Inventor NAMBU, Mami
A concentrating membrane used to concentrate biological particles, the concentrating membrane including a hydrophilic composite porous membrane that comprises a porous base material and a hydrophilic resin coating that coats at least one main surface and the inner pore surfaces of the porous base material, the hydrophilic composite porous membrane being such that the ratio t/x of the membrane thickness t (μm) and the average pore size x (μm) measured by palm porometer is 50-630. A device 10 for concentrating biological particles 50, the device 10 comprising: a housing 20 having an inlet 21 and an outlet 22, the housing 20 being such that a to-be-treated liquid 40 containing biological particles 50 and water is injected from the inlet 21 and discharged from the outlet 22 by the pressure difference between the inlet 21 and the outlet 22; a concentrating membrane 30 provided in the housing 20 so as to separate the inlet 21 and the outlet 22, the concentrating membrane 30 being a hydrophilic porous membrane to which the biological particles 50 do not adsorb, and allowing an effluent 42, which is a liquid in which the concentration of biological particles 50 has been decreased from that of the to-be-treated liquid 40, to penetrate from the surface on the inlet 21 side to the surface on the outlet 22 side; and a concentration space portion 24 for accommodating a concentrated liquid 41, which is a liquid in which the concentration of biological particles 50 is increased over that of the to-be-treated liquid 40 by the concentrating membrane 30, the concentration space portion 24 being located on the upstream side of the concentrating membrane 30 in the housing 20.
3.WO/2020/185775MATERIALS AND METHODS FOR REDUCING NUCLEIC ACID DEGRADATION IN BACTERIA
WO 17.09.2020
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/US2020/021886 Applicant UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. Inventor CRECY, Valerie, Anne De
The present disclosure is directed to materials and methods for reducing heterologous DNA damage in bacteria (i.e., induce resistance to host restriction enzymes) by modifying the heterologous DNA to include one or more deazapurine bases.
4.WO/2020/183131COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CAR
WO 17.09.2020
Int.Class A61K 35/13
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
13Tumour cells, irrespective of tissue of origin
Appl.No PCT/GB2020/050535 Applicant AUTOLUS LIMITED Inventor PULÉ, Martin
There is provided method for making a cell composition which comprises step of transducing a population of cells with a mixture of at least two viral vectors, wherein at least one vector comprises a nucleic acid sequence which encodes a chimeric antigen receptor (CAR); and wherein at least one vector comprises a nucleic acid encoding an activity modulator which modulates the activity of the CAR, of a cell expressing the CAR, or of a target cell. There is also provided a cell composition made by such a method and its use in the treatment of diseases such as cancer.
5.WO/2020/182860NOROVIRUS-LIKE PARTICLES WITH IMPROVED STABILITY
WO 17.09.2020
Int.Class C07K 14/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
Appl.No PCT/EP2020/056461 Applicant ICON GENETICS GMBH Inventor JARCZOWSKI, Franziska
The invention provides a norovirus genogroup I VP1 capsid protein having an amino acid sequence wherein the amino acid sequence stretch in the P domain Ala-Ala- Leu-Leu/Val-His-Tyr is modified to Ala-Ala-Leu-LeuNal-Arg/Lys-Tyr.
6.WO/2020/184730DENGUE VIRUS VACCINE
WO 17.09.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/JP2020/012569 Applicant TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE Inventor KOHARA, Michinori
The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.
7.WO/2020/186229TLR4-TLR7 LIGAND FORMULATIONS AS VACCINE ADJUVANTS
WO 17.09.2020
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
Appl.No PCT/US2020/022786 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor CARSON, Dennis A.
A method to enhance an immune response in a mammal, and a composition comprising liposomes, a TLR4 agonist and a TLR7 agonist, are provided.
8.WO/2020/185898INFLUENZA VIRUS MUTANTS AND USES THEREFOR
WO 17.09.2020
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/US2020/022104 Applicant THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF AGRICULTURE Inventor KAPCZYNSKI, Darrell, R.
The disclosure relates to mutant recombinant influenza virus gene segment 7 with at least one mutation that modulates expression of M2 and M42 polypeptide. Also disclosed are recombinant influenza viruses comprising the mutant influenza virus gene segment 7, compositions comprising the mutant recombinant influenza virus gene segment 7, use of such mutant recombinant influenza virus gene segment 7 and mutant recombinant Influenza viruses.
9.WO/2020/186238SYNCYTIAL ONCOLYTIC HERPES SIMPLEX MUTANTS AS POTENT CANCER THERAPEUTICS
WO 17.09.2020
Int.Class A61K 35/763
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
763Herpes virus
Appl.No PCT/US2020/022806 Applicant RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL Inventor CRIPE, Timothy, P.
The disclosure provides a non-natural herpes simplex virus ("HSV"), compositions comprising, or alternatively consisting essentially of, or yet further consisting of the HSV, and methods of producing the HSV, or infecting a cell with the HSV. Also provided herein are methods of treating cancer or inhibiting the growth or metastasis of cancer cell in a subject in need thereof.
10.20200282077ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND USE FOR INHIBITING ANGIOGENESIS
US 10.09.2020
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No 16765758 Applicant 4D MOLECULAR THERAPEUTICS INC. Inventor David H. KIRN

Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.